2022 Fiscal Year Final Research Report
Development of novel inhaled bronchial asthma therapy targeting CCL-15 using siRNA dry powder
Project/Area Number |
19K17637
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 53030:Respiratory medicine-related
|
Research Institution | Hiroshima University |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Keywords | 気管支喘息 / CCL15 / 喘息モデルマウス / siRNA |
Outline of Final Research Achievements |
We measured CCL-15 levels in induced sputum (IS) from asthmatic subjects and healthy controls. In asthmatic subjects, IS CCL-15 levels were elevated, compared with that of healthy controls. CCL-15 levels in IS were also found to correlate with serum periostin levels. The CCL-9, the mouse ortholog of CCL15, levels in the bronchoalveolar lavage fluids (BALFs) of the asthma models were significantly increased compared with those of control mice. An immunohistochemical examination showed that the expression of CCL-9 was detected in the bronchial epithelium, airway smooth muscle cells, vascular endothelial cells, and subepithelial inflammatory cells in the mice.
|
Free Research Field |
呼吸器内科
|
Academic Significance and Societal Importance of the Research Achievements |
本研究により、喘息気道においてCCL15の発現が亢進していることが示され、CCL15が喘息の病態や難治化に関わっている可能性があると考えられた。これらの結果より、CCL15は気管支喘息の診断や気道炎症の評価において役立つバイオマーカーとして有望と考えられ、難治性喘息の病態解明や喘息診断・気道炎症評価における新たな検査法の開発、さらにはCCL15を標的とした新規気管支喘息治療の開発につながる可能性がある。
|